Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Single-arm Phase I Study to Assess the Safety, and Tolerability of HY001N Cell Injection in Patients With Autoimmune Hemolytic Anemia After Failure of Three or More Lines of Therapy

NCT07748533 is registered in ClinicalTrials.gov with Juventas Cell Therapy Ltd. as lead sponsor.

NCT NCT07748533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07748533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Single-arm Phase I Study to Assess the Safety, and Tolerability of HY001N Cell Injection in Patients With Autoimmune Hemolytic Anemia After Failure of Three or More Lines of Therapy
Lead sponsor
Juventas Cell Therapy Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 2, 2026
Completion date
October 1, 2028
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia (aiha)